<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">CARISOPRODOL</span><br/>(kar-eye-soe-proe'dole)<br/><span class="topboxtradename">Rela, </span><span class="topboxtradename">Soma<br/></span><b>Classifications:</b> <span class="classification">autonomic nervous system agent</span>; <span class="classification">skeletal muscle relaxant: central-acting</span><br/><b>Prototype: </b>Cyclobenzaprine<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>350 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Propanediol derivative carbamate with central depressant action pharmacologically related to meprobamate. Precise action mechanism
         of CNS depression is not clear. Skeletal muscle relaxant effect, unlike that of neuromuscular blocking agents, appears to
         be due to sedative action. Voluntary motor function is not lost, but there may be slight reduction in muscle tone leading
         to relief of pain and discomfort of muscle spasm.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Effective spasmolytic and reduces pain associated with acute musculoskeletal disorders.</p>
<h1><a name="uses">Uses</a></h1>
<p>Skeletal muscle spasm, stiffness, and pain in a variety of musculoskeletal disorders and to relieve spasticity and rigidity
         in cerebral palsy.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to carisoprodol and related compounds (e.g., meprobamate, tybamate); acute intermittent porphyria; children
         
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Impaired liver or kidney function, addiction-prone individuals.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Muscle Spasm</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 350 mg t.i.d.<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span>
<i>&gt;5 y</i>, 25 mg/kg/d in 4 divided doses<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give with food, as needed, to reduce GI symptoms. Last dose should be taken at bedtime.</li>
<li>Store in tightly closed container.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span> Eosinophilia, asthma, fever, <span class="speceff-life">anaphylactic shock</span>. <span class="typehead">CV:</span> Tachycardia, postural hypotension, facial flushing. <span class="typehead">GI:</span> Nausea, vomiting, hiccups. <span class="typehead">CNS:</span>
<span class="speceff-common">Drowsiness, dizziness,</span> vertigo, ataxia, tremor, headache, irritability, depressive reactions, syncope, insomnia. <span class="typehead">Skin:</span> Skin rash, erythema multiforme, pruritus. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Alcohol,</b>
<span class="classification">cns depressants</span> potentiate CNS effects. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead"> Onset:</span> 30 min. <span class="typehead">Duration:</span> 46 h. <span class="typehead">Distribution:</span> Crosses placenta. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Excreted by kidneys; excreted in breast milk (24 times the plasma concentrations). <span class="typehead">Half-Life:</span> 8 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for allergic or idiosyncratic reactions that generally occur from the first to the fourth dose in patients taking
            the drug for the first time. Symptoms usually subside after several hours; they are treated by supportive and symptomatic
            measures.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Avoid driving and other potentially hazardous activities until response to the drug has been evaluated. Drowsiness is a common
            side effect and may require reduction in dosage.
         </li>
<li>Report to physician if symptoms of dizziness and faintness persist. Symptoms may be controlled by making position changes
            slowly and in stages.
         </li>
<li>Do not take alcohol or other CNS depressants (effects may be additive) unless otherwise directed by physician.</li>
<li>Discontinue drug and notify physician if skin rash, diplopia, dizziness, or other unusual signs or symptoms appear.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>